Table 2.

Patient demographics

	All N = 191	Curcumin Gel N = 64 (33.5%)	HPR Plus™ N = 65 (34.0%)	Placebo N = 62 (32.5%)
Age (years)
Mean [95% CI]	59.8 [58.3, 61.3]	59.0 [56.2, 61.8]	60.7 [58.0, 63.3]	59.8 [57.4, 62.2]
Race
White/Caucasian	167 (87.4%)	55 (85.9%)	55 (84.6%)	57 (91.9%)
Black/African American	21 (11.0%)	8 (12.5%)	9 (13.8%)	4 (6.5%)
Asian	2 (1.%)	0 (0.0%)	1 (1.5%)	1 (1.6%)
Unknown	1 (0.5%)	1 (1.6%)	0 (0.0%)	0 (0.0%)
Ethnicity
Hispanic	3 (1.4%)	2 (3.1%)	0 (0.0%)	1 (1.6%)
Non-Hispanic	186 (97.4%)	62 (96.9%)	63 (96.9%)	61 (98.4%)
Unknown	2 (1.1%)	0 (0.0%)	2 (3.1%)	0 (0.0%)
Marital status
Married	119 (62.3%)	45 (70.3%)	37 (56.9%)	37 (59.7%)
Domestic partner	1 (0.5%)	0 (0.0%)	0 (0.0%)	1 (1.6%)
Divorced	30 (15.7%)	5 (7.8%)	9 (13.8%)	16 (25.8%)
Separated	2 (1.1%)	1 (1.6%)	0 (0.0%)	1 (1.1%)
Single	18 (9.4%)	8 (12.5%)	8 (12.3%)	2 (3.2%)
Widowed	19 (10%)	5 (7.8%)	10 (15.4%)	4 (6.5%)
Tumor location
Left	86 (45%)	29 (45.3%)	27 (41.5%)	30 (48.4%)
Right	103 (53.9%)	35 (54.7%)	37 (56.9%)	31 (50%)
Tumor stage
DCIS	28 (14.7%)	5 (7.8%)	12 (18.5%)	11 (17.7%)
I	85 (44.5%)	34 (53.1%)	29 (44.6%)	22 (35.5%)
II	54 (28.3%)	16 (25%)	18 (27.7%)	20 (32.3%)
III	20 (10.5%)	7 (10.9%)	5 (7.7%)	8 (12.9%)
IV	2 (1.1%)	2 (3.1%)	0 (0.0%)	0 (0.0%)
Radiation type
IMRT	5 (2.6%)	1 (1.6%)	2 (3.1%)	2 (3.2%)
3D conformai whole breast	184 (96.3%)	63 (98.4%)	62 (95.4%)	59 (95.2%)
Radiation boost
Yes	180 (94.2%)	60 (93.8%)	61 (93.8%)	59 (95.2%)
No	9 (4.7%)	4 (6.3%)	3 (4.6%)	2 (3.2%)
Prescribed radiation dose (Gy)
Mean [95% CI]	59 [58.3, 61.3]	58.4 [57.0, 59.8]	59.5 [58.4, 60.7]	59.1 [57.8, 60.4]
Breast field separation (cm)
Mean [95% CI]	23.1 [22.4, 23.7]	22.6 [21.6, 23.6]	23.8 [22.8, 24.9]	22.8 [21.4, 24.2]
Prior chemotherapy
Yes	90 (47.1%)	34 (53.1%)	29 (44.6%)	27 (43.5%)
No	99 (51.8%)	30 (46.9%)	35 (53.8%)	34 (54.8%)
Hormone treatment
Yes	41 (21.5%)	12 (18.8%)	16 (24.6%)	13 (21%)
No	148 (77.5%)	52 (81.2%)	48 (73.8%)	48 (77.4%)
Herceptin treatment
Yes	19 (10.0%)	8 (12.5%)	8 (12.3%)	3 (4.8%)
No	170 (89.0%)	56 (87.5%)	56 (86.2%)	58 (93.5%)